For example, targeting TGF-β in ovarian cancer has shown promise in preclinical studies, where the inhibition of TGF-β signaling reduced EMT, inhibited tumor growth, and enhanced chemotherapy effectiveness [47,48]. Here, TGFB1 is linked to ovarian carcinoma.